biotech

biotech Articles

The December 14 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Gritstone shares made a handy gain on Friday after the firm received a key update from the FDA.
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Proteostasis Therapeutics shares jumped on Monday after the company announced that a new licensing agreement with Genentech.
Applied Genetic Technologies shares dropped on Thursday after the company announced that its midstage eye study did not live up to expectations.
Marinus shares backed off on Wednesday when the firm announced that it would be conducting a secondary offering. The company is capitalizing on its success earlier this week when it announced...
Neurocrine Bio shares dipped on Wednesday after the company announced that its midstage Tourette syndrome study did not live up to expectations.
The November 30 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Ra Pharmaceuticals shares jumped on Monday after the company announced positive mid-stage results for the treatment of generalized myasthenia gravis.
Marinus Pharmaceuticals shares made a handy gain on Monday after the company announced positive results from its midstage trial in women with postpartum depression.
Gilead shares made a slight gain early on Monday after the firm announced that there would be a big change at the top, in terms of its senior management. Not to mention, this executive is coming from...
24/7 Wall St. takes a look at what is coming up in the FDA calendar regarding biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest of 2018.
Moderna entered the market quietly on Friday after it priced what is being called the biggest biotech IPO to date.
GBT shares dipped on Friday after the company announced that it would be conducting a secondary offering. This offering comes on the heels of a key FDA approval.
Supernus Pharmaceuticals shares dipped on Thursday despite the firm posted positive results from two of its late-stage studies in children for the treatment of attention deficit hyperactivity...